|
H · S · G COMPLETED CLINICAL TRIALS
RID-HD: RIluzole Dosing in HD In September 1999, the HSG received funding from the US Food and Drug Administration's Orphan Products Division for a multicenter placebo controlled study of riluzole under the principal direction of Frederick Marshall, MD at the University of Rochester and Merit Cudkowicz, MD at Massachusetts General Hospital. The "Riluzole Dosing in HD" (RID-HD) study was designed to assess riluzole's short-term impact on motor, cognitive and behavioral symptoms of HD and to gather information on the safety and tolerability of riluzole. Enrollment in the RID-HD trial began in January 2000 and was completed in August 2000. The results of RID-HD trial were presented at the 19th International Meeting of the World Federation of Neurology Research Group on Huntington's Disease, August 25-28, 2001, Copenhagen, Denmark. A copy of the abstract can be found at: www.huntington-study-group.org/RID-HD Abstract.htm. Another informational piece from Dr. Marshall about RID-HD is also available at: www.huntington-study-group.org/RID-HDCommentsDec2003
|
HDSA Center of Excellence at Hennepin County Medical Center